Department of Molecular Medicine DMM, University of Padua, Padua, Italy.
Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, 35128, Padua, Italy.
J Exp Clin Cancer Res. 2019 May 9;38(1):190. doi: 10.1186/s13046-019-1205-0.
One of the most potent costimulatory molecules involved in the recognition and killing of tumor cells is CD80. However, its role and the molecular mechanisms regulating its expression in sporadic colorectal carcinogenesis remain elusive. Here, we provide evidence for CD80 overexpression in human colon epithelial cells derived from preneoplastic mucosa.
Expression of CD80 on colonic epithelial cells isolated from normal human colonic mucosa, preneoplastic and neoplastic specimens was assessed by flow cytometry. WT and CD80KO mice received azoxymethane to induce colon preneoplastic lesions and sacrificed to perform histology, flow cytometry analysis and immunohistochemistry of colonic mucosa. Some WT mice were treated with a monoclonal anti-CD80 antibody following AOM administration. Primary colon epithelial cells and CT26 cell line were used to quantify the expression of CD80 in response to pro-oxidant stimuli. Specific pharmacological inhibitors and siRNA silencing were used to inhibit MAPK pathways and STAT3.
CD80 expression was significantly increased in colon epithelial cells of human preneoplastic lesions. In the AOM model, CD80 impairment by administration of neutralizing antibodies or use of CD80 knockout mice enhanced dysplasia development. In vitro, CD80 upregulation was induced by oxidative stress in colon cancer cells and primary colon epithelial cells. In addition, reactive oxygen species could induce CD80 expression via the JNK and p38 MAPK pathways, that activated STAT3 transcription factor in colon cancer epithelial cells.
This study provide evidence for a major role of CD80 in orchestrating immune surveillance of colon preneoplastic lesions and might help to develop novel approaches that exploit anti-tumor immunity to prevent and control colon cancer.
在识别和杀伤肿瘤细胞过程中,涉及的最有效的共刺激分子之一是 CD80。然而,其在散发性结直肠癌发生过程中的作用及其表达的分子机制仍不清楚。在此,我们提供了 CD80 在人结直肠上皮细胞中过度表达的证据,这些细胞来自于癌前黏膜。
通过流式细胞术评估从正常人类结直肠黏膜、癌前和肿瘤标本中分离的结肠上皮细胞上 CD80 的表达。WT 和 CD80KO 小鼠接受氧化偶氮甲烷(AOM)诱导结肠癌前病变,并进行组织学、流式细胞术分析和结肠黏膜免疫组化分析。一些 WT 小鼠在 AOM 给药后接受单克隆抗 CD80 抗体治疗。使用原发性结肠上皮细胞和 CT26 细胞系来定量分析 CD80 在应对促氧化剂刺激时的表达情况。使用特定的药理学抑制剂和 siRNA 沉默来抑制 MAPK 通路和 STAT3。
CD80 的表达在人癌前病变的结肠上皮细胞中显著增加。在 AOM 模型中,通过给予中和抗体或使用 CD80 敲除小鼠,CD80 功能受损可增强发育不良的发生。在体外,氧化应激可诱导结肠癌细胞和原发性结肠上皮细胞中 CD80 的上调。此外,活性氧可以通过 JNK 和 p38 MAPK 通路诱导 CD80 的表达,从而激活结肠癌细胞上皮细胞中的 STAT3 转录因子。
本研究为 CD80 在协调结肠癌前病变的免疫监视中发挥主要作用提供了证据,并可能有助于开发利用抗肿瘤免疫来预防和控制结肠癌的新方法。